Lexicon Pharmaceuticals Future Growth
Future criteria checks 2/6
Lexicon Pharmaceuticals is forecast to grow earnings and revenue by 14.7% and 56.2% per annum respectively. EPS is expected to grow by 24.3% per annum. Return on equity is forecast to be -115% in 3 years.
Key information
14.7%
Earnings growth rate
24.3%
EPS growth rate
Biotechs earnings growth | 27.9% |
Revenue growth rate | 56.2% |
Future return on equity | -115.0% |
Analyst coverage | Good |
Last updated | 17 Oct 2024 |
Recent future growth updates
Recent updates
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
Oct 16Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Aug 03Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
May 28Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
Mar 12Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
Jan 26Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?
Apr 25Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?
Jan 04Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 121 | -165 | N/A | N/A | 6 |
12/31/2025 | 51 | -219 | N/A | N/A | 6 |
12/31/2024 | 16 | -210 | N/A | N/A | 6 |
6/30/2024 | 4 | -202 | -196 | -196 | N/A |
3/31/2024 | 2 | -194 | -186 | -185 | N/A |
12/31/2023 | 1 | -177 | -162 | -162 | N/A |
9/30/2023 | 1 | -158 | -135 | -133 | N/A |
6/30/2023 | 0 | -131 | -112 | -111 | N/A |
3/31/2023 | 0 | -110 | -99 | -97 | N/A |
12/31/2022 | 0 | -102 | -90 | -89 | N/A |
9/30/2022 | 0 | -97 | -90 | -90 | N/A |
6/30/2022 | 0 | -97 | -88 | -88 | N/A |
3/31/2022 | 0 | -90 | -87 | -85 | N/A |
12/31/2021 | 0 | -88 | -88 | -87 | N/A |
9/30/2021 | 0 | -68 | -100 | -98 | N/A |
6/30/2021 | 7 | 38 | 38 | -122 | N/A |
3/31/2021 | 16 | -13 | 14 | -146 | N/A |
12/31/2020 | 24 | -59 | 17 | -143 | N/A |
9/30/2020 | 33 | -104 | 27 | -133 | N/A |
6/30/2020 | 320 | 39 | 98 | 98 | N/A |
3/31/2020 | 321 | 85 | 117 | 117 | N/A |
12/31/2019 | 322 | 130 | 114 | 114 | N/A |
9/30/2019 | 330 | 164 | 111 | 111 | N/A |
6/30/2019 | 43 | -89 | -102 | -102 | N/A |
3/31/2019 | 47 | -101 | -128 | -127 | N/A |
12/31/2018 | 63 | -121 | -149 | -149 | N/A |
9/30/2018 | 81 | -126 | -155 | -155 | N/A |
6/30/2018 | 101 | -129 | -167 | -167 | N/A |
3/31/2018 | 99 | -130 | N/A | -147 | N/A |
12/31/2017 | 92 | -123 | N/A | -185 | N/A |
9/30/2017 | 80 | -133 | N/A | -200 | N/A |
6/30/2017 | 81 | -138 | N/A | -202 | N/A |
3/31/2017 | 89 | -141 | N/A | -217 | N/A |
12/31/2016 | 79 | -131 | N/A | -176 | N/A |
9/30/2016 | 188 | -22 | N/A | 139 | N/A |
6/30/2016 | 160 | -22 | N/A | 149 | N/A |
3/31/2016 | 141 | -11 | N/A | 165 | N/A |
12/31/2015 | 130 | -5 | N/A | 185 | N/A |
9/30/2015 | 24 | -94 | N/A | -86 | N/A |
6/30/2015 | 24 | -100 | N/A | -81 | N/A |
3/31/2015 | 24 | -98 | N/A | -69 | N/A |
12/31/2014 | 23 | -100 | N/A | -76 | N/A |
9/30/2014 | 3 | -115 | N/A | -93 | N/A |
6/30/2014 | 3 | -106 | N/A | -96 | N/A |
3/31/2014 | 2 | -109 | N/A | -97 | N/A |
12/31/2013 | 2 | -104 | N/A | -91 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LXRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LXRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LXRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LXRX's revenue (56.2% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: LXRX's revenue (56.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LXRX is forecast to be unprofitable in 3 years.